Ceapro Inc (CZO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Ceapro Inc (CZO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10028
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ceapro Inc (Ceapro) is a biotechnology company which develops proprietary extraction technologies for use in the production of extracts and active ingredients from oats and other renewable plant resources. The company’s extracts are also used in nutraceutical, cosmeceutical, and therapeutics products for humans and animals. Ceapro’s portfolio includes natural active ingredients comprising oat avenanthramides, oat oil, oat peptides, oat beta glucan, and lupin peptides; and veterinary products including oat shampoo, ear cleanser and dermal complex/conditioner. The company offers its products in Canada, United States, Germany, China and other countries. Ceapro is headquartered in Edmonton, Alberta, Canada.

Ceapro Inc (CZO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ceapro Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ceapro Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ceapro Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ceapro Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Ceapro Enters into Agreement with Montreal Heart Institute 11
Licensing Agreements 12
Ceapro Expands Licensing Agreement with University of Alberta 12
Symrise Enters Into Licensing Agreement With Ceapro 13
Equity Offering 14
Ceapro Raises USD3.3 Million in Second and Final Tranche of Private Placement of Units 14
Ceapro Raises USD4.4 Million in First Tranche of Brokered Private Placement of Units 16
Debt Offering 18
Ceapro Raises USD0.24 Million in Second Tranche of Private Placement of Debentures Due 2016 18
Ceapro Inc – Key Competitors 19
Ceapro Inc – Key Employees 20
Ceapro Inc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Aug 28, 2018: Ceapro reports 2018 second quarter and six-month financial results and operational highlights 22
May 17, 2018: Ceapro Announces 2018 First Quarter Results 23
Apr 20, 2018: Ceapro Reports 2017 Financial Results 24
Nov 15, 2017: Ceapro Reports 2017 Third Quarter Business Update and Financial Results 25
Aug 18, 2017: Ceapro Reports 2017 Second Quarter Business Update and Financial Results 27
May 17, 2017: Ceapro Reports 2017 First Quarter Development Highlights and Financial Results 29
Apr 06, 2017: Ceapro Reports 2016 Financial Results and Provides Corporate Update 31
Legal and Regulatory 33
Aug 27, 2018: Ceapro settles judgements in AVAC actions 33
Product News 34
May 29, 2018: Ceapro Confirms Excellent Bioavailability of its New Water Soluble Chemical Complex Coenzyme Q10-Beta Glucan 34
Other Significant Developments 36
Apr 23, 2018: Ceapro Provides Corporate Update – Company well poised to transition to its next phase of growth for expansion into the profitable nutraceutical sector 36
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
Ceapro Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ceapro Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ceapro Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Ceapro Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ceapro Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ceapro Enters into Agreement with Montreal Heart Institute 11
Ceapro Expands Licensing Agreement with University of Alberta 12
Symrise Enters Into Licensing Agreement With Ceapro 13
Ceapro Raises USD3.3 Million in Second and Final Tranche of Private Placement of Units 14
Ceapro Raises USD4.4 Million in First Tranche of Brokered Private Placement of Units 16
Ceapro Raises USD0.24 Million in Second Tranche of Private Placement of Debentures Due 2016 18
Ceapro Inc, Key Competitors 19
Ceapro Inc, Key Employees 20
Ceapro Inc, Subsidiaries 21

List of Figures
Ceapro Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ceapro Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ceapro Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Ceapro Inc (CZO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NeuroSearch AS (NEUR):企業の財務・戦略的SWOT分析
    NeuroSearch AS (NEUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Tanzania Electric Supply Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Tanzania Electric Supply Co Ltd (TANESCO), formerly Tanganyika Electric Supply Co Ltd, is a government-owned integrated power company. The company’s operations are regulated by the Ministry of Energy and Minerals. It generates, transmits, distributes and supplies electricity. TANESCO generat …
  • CS Wind Corp (112610):企業の財務・戦略的SWOT分析
    Summary CS Wind Corp (CS Wind) formerly Choong San Corp, is a global wind tower company that manufactures and distributes aluminum platforms used for wind power generation towers. The company’s products include transition piece, wind tower, tower internal parts, oil and gas pipes, and plant equipmen …
  • Rothschild Bank AG:企業の戦略・SWOT・財務情報
    Rothschild Bank AG - Strategy, SWOT and Corporate Finance Report Summary Rothschild Bank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Slavneft-Yaroslavnefteorgsintez (JNOS):企業の財務・戦略的SWOT分析
    Summary Slavneft-Yaroslavnefteorgsintez (Slavneft-YANOS), a subsidiary of Slavneft, is an oil and gas company that offers refined petroleum products. The company offers products such as bitumen, motor gasoline, diesel fuel, jet fuel, motor oil, transmission oil, turbine oil, compressor oil, industri …
  • Midea Group Co Ltd:企業の戦略・SWOT・財務情報
    Midea Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Midea Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Clalit Health Services:企業の戦略的SWOT分析
    Clalit Health Services - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Resverlogix Corp (RVX)-製薬・医療分野:企業M&A・提携分析
    Summary Resverlogix Corp (Resverlogix) is an epigenetics company that develops small molecule therapeutics for Bromodomain and ExtraTerminal Domain (BET) inhibition. The company provides lead product such as RVX-208 (apabetalone), is a BET inhibitor under phase III clinical trial. Its RVX-208 is bei …
  • Tokyo Electron Ltd (8035):企業の財務・戦略的SWOT分析
    Tokyo Electron Ltd (8035) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • hVIVO Plc (HVO):企業の財務・戦略的SWOT分析
    Summary hVIVO Plc (hVIVO), formerly Retroscreen Virology Ltd is a biopharma company that develops human-based analytical platform to accelerate drug discovery and development. The company enables organisations to discover drugs and diagnostics and accelerate new product development. It uses human di …
  • British American Tobacco Plc (BATS):企業の財務・戦略的SWOT分析
    British American Tobacco Plc (BATS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • St. Jude Medical, Inc.:企業のM&A・事業提携・投資動向
    St. Jude Medical, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's St. Jude Medical, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Witte Molen N.V.:企業の戦略・SWOT・財務情報
    Witte Molen N.V. - Strategy, SWOT and Corporate Finance Report Summary Witte Molen N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Cyient Ltd (CYIENT):企業の財務・戦略的SWOT分析
    Cyient Ltd (CYIENT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • RigNet Inc (RNET):企業の財務・戦略的SWOT分析
    RigNet Inc (RNET) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Spero Therapeutics Inc (SPRO):製薬・医療:M&Aディール及び事業提携情報
    Summary Spero Therapeutics Inc. (Spero) is a clinical-stage biopharmaceutical company. It is engaged in developing, identifying and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections. Its product pipeline includes SPR994 oral gram-negative program, SPR741and SPR206 …
  • Nationwide Financial Services, Inc.:企業の戦略的SWOT分析
    Nationwide Financial Services, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Staples, Inc.:企業の戦略・SWOT・財務分析
    Staples, Inc. - Strategy, SWOT and Corporate Finance Report Summary Staples, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • TE Connectivity Ltd.:企業の戦略・SWOT・財務情報
    TE Connectivity Ltd. - Strategy, SWOT and Corporate Finance Report Summary TE Connectivity Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Interconexion Electrica SA ESP (ISA):企業の財務・戦略的SWOT分析
    Interconexion Electrica SA ESP (ISA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆